{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":3,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07252232\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RASolute 304","nct_id":"NCT07252232","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rasolute-304-nct07252232. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"RASolute 304","arms":[{"description":"study drug","label":"daraxonrasib","type":"EXPERIMENTAL"},{"description":"Patients randomized to the comparator control arm will receive SOC observation.","label":"SOC Observation","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2030-07-10","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma (PDAC)","Resected Pancreatic Adenocarcinoma"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"daraxonrasib","type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"Revolution Medicines, Inc.","official_title":"RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-05-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS) per Investigator","timeFrame":"Up to approximately 5 years"}],"references":[],"start_date":{"date":"2025-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","url":"https://clinicaltrials.gov/study/NCT07252232"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rasolute-304-nct07252232"}